Pre-Activity Questions

Currently, how confident are you in your ability to: *

Please use the scale: 1=Not at all confident , 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Extremely confident

	1	2	3	4	5
Understand and apply the use of new therapeutics to patients with asthma to improve outcomes?	Understand and apply the use of new therapeutics to patients with asthma to improve outcomes? - 1	Understand and apply the use of new therapeutics to patients with asthma to improve outcomes? - 2	Understand and apply the use of new therapeutics to patients with asthma to improve outcomes? - 3	Understand and apply the use of new therapeutics to patients with asthma to improve outcomes? - 4	Understand and apply the use of new therapeutics to patients with asthma to improve outcomes? - 5
Utilize individualized treatment plans when treating your patients with asthma?	Utilize individualized treatment plans when treating your patients with asthma? - 1	Utilize individualized treatment plans when treating your patients with asthma? - 2	Utilize individualized treatment plans when treating your patients with asthma? - 3	Utilize individualized treatment plans when treating your patients with asthma? - 4	Utilize individualized treatment plans when treating your patients with asthma? - 5

Targeted therapy has the ability to improve outcomes if: *

There is an understanding of different symptoms of asthma

There is an understanding of the mechanism of action

There is an understanding that all patients do not respond to corticosteroids

There is an understanding in the diagnosis of patients with asthma

Potential biomarkers in elucidating and predicating therapeutic response include: *

FEV1

Immunoglobulin levels

C-reactive protein

Total IgE level

Studies suggest a patient's adherence levels rise when: *

A patient's confidence in the clinician rises

A clinician's confidence in the patient rises

There is no correlation between patient vs. clinician confidence

Patients are held accountable in taking therapeutics

Regarding impairment and risk, a clinician’s recommendation to use anti IL-5 for their patient is dependent on: *

Exacerbation rate and lung function

Exacerbation rate and quality of life

Lung function and quality of life

Exacerbation rate, lung function, and quality of life

Studies suggest that which of the following may give insight into endotype? *

Objective measures of airflow, FeNO, and peripheral blood markers

Objective measures of airflow and FeNO

FeNO and peripheral blood markers

Objective measures of airflow and peripheral blood markers

Which device reveals a large response to a bronchodilator, giving clinicians insight into patient responce to medication? *

Peak Flow Meters

Lung Volumes and Airways Resistance

Simple spirometry

Metered-dose Inhalers

Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses.

Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with asthma. *

Please use this scale for your current use: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me

	1	2	3	4	5	N/A
Utilize up-to-date asthma management guidelines to evaluate patient development.	Utilize up-to-date asthma management guidelines to evaluate patient development. - 1	Utilize up-to-date asthma management guidelines to evaluate patient development. - 2	Utilize up-to-date asthma management guidelines to evaluate patient development. - 3	Utilize up-to-date asthma management guidelines to evaluate patient development. - 4	Utilize up-to-date asthma management guidelines to evaluate patient development. - 5	Utilize up-to-date asthma management guidelines to evaluate patient development. - N/A
Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies.	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - 1	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - 2	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - 3	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - 4	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - 5	Apply clinical trial data to patients with asthma to assess the efficacy and safety of new and emerging therapies. - N/A
Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans.	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - 1	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - 2	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - 3	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - 4	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - 5	Implement the practice of understanding the mechanism of action in patients with moderate-to-severe persistent asthma to apply precise personalized treatment plans. - N/A

Leave this field blank

Elsevier CME

CHEST 2016: Understanding the Role of Targeted Biologic Therapies in the Treatment of Patients with Moderate-to-Severe, Persistent Asthma

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Course navigation

You are here

CHEST 2016: Understanding the Role of Targeted Biologic Therapies in the Treatment of Patients with Moderate-to-Severe, Persistent Asthma

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Course navigation